Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

STVN vs BDX vs AVTR vs BAX vs TMO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
STVN
Stevanato Group S.p.A.

Medical - Instruments & Supplies

HealthcareNYSE • IT
Market Cap$4.92B
5Y Perf.-10.7%
BDX
Becton, Dickinson and Company

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$55.53B
5Y Perf.-0.5%
AVTR
Avantor, Inc.

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$5.67B
5Y Perf.-77.9%
BAX
Baxter International Inc.

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$9.04B
5Y Perf.-77.4%
TMO
Thermo Fisher Scientific Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$176.36B
5Y Perf.-12.1%

STVN vs BDX vs AVTR vs BAX vs TMO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
STVN logoSTVN
BDX logoBDX
AVTR logoAVTR
BAX logoBAX
TMO logoTMO
IndustryMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Diagnostics & Research
Market Cap$4.92B$55.53B$5.67B$9.04B$176.36B
Revenue (TTM)$1.18B$21.36B$6.55B$11.32B$45.20B
Net Income (TTM)$139M$1.14B$-551M$-1.10B$6.86B
Gross Margin29.0%46.5%32.1%30.1%39.4%
Operating Margin16.5%10.6%-4.3%-2.7%17.8%
Forward P/E29.3x12.3x10.6x9.2x19.1x
Total Debt$471M$19.18B$3.95B$10.00B$40.85B
Cash & Equiv.$131M$851M$365M$1.97B$9.86B

STVN vs BDX vs AVTR vs BAX vs TMOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

STVN
BDX
AVTR
BAX
TMO
StockJul 21May 26Return
Stevanato Group S.p… (STVN)10089.3-10.7%
Becton, Dickinson a… (BDX)10099.5-0.5%
Avantor, Inc. (AVTR)10022.1-77.9%
Baxter Internationa… (BAX)10022.6-77.4%
Thermo Fisher Scien… (TMO)10087.9-12.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: STVN vs BDX vs AVTR vs BAX vs TMO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BDX leads in 4 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Thermo Fisher Scientific Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. BAX also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
STVN
Stevanato Group S.p.A.
The Healthcare Pick

STVN lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
BDX
Becton, Dickinson and Company
The Income Pick

BDX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 0.66, yield 2.7%
  • Rev growth 8.2%, EPS growth -0.5%, 3Y rev CAGR 5.0%
  • Lower volatility, beta 0.66, Low D/E 75.5%, current ratio 1.11x
  • PEG 0.74 vs TMO's 9.05
Best for: income & stability and growth exposure
AVTR
Avantor, Inc.
The Value Angle

Among these 5 stocks, AVTR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
BAX
Baxter International Inc.
The Defensive Pick

BAX ranks third and is worth considering specifically for defensive.

  • Beta 1.37, yield 3.9%, current ratio 2.31x
  • 3.9% yield, vs TMO's 0.4%, (1 stock pays no dividend)
Best for: defensive
TMO
Thermo Fisher Scientific Inc.
The Long-Run Compounder

TMO is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 229.1% 10Y total return vs BDX's 80.2%
  • 15.2% margin vs BAX's -9.7%
  • 6.4% ROA vs BAX's -5.4%, ROIC 7.5% vs -1.4%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthBDX logoBDX8.2% revenue growth vs AVTR's -3.4%
ValueBDX logoBDXLower P/E (12.3x vs 19.1x), PEG 0.74 vs 9.05
Quality / MarginsTMO logoTMO15.2% margin vs BAX's -9.7%
Stability / SafetyBDX logoBDXBeta 0.66 vs AVTR's 1.54
DividendsBAX logoBAX3.9% yield, vs TMO's 0.4%, (1 stock pays no dividend)
Momentum (1Y)BDX logoBDX+51.8% vs BAX's -41.8%
Efficiency (ROA)TMO logoTMO6.4% ROA vs BAX's -5.4%, ROIC 7.5% vs -1.4%

STVN vs BDX vs AVTR vs BAX vs TMO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

STVNStevanato Group S.p.A.

Segment breakdown not available.

BDXBecton, Dickinson and Company
FY 2025
Medical
52.5%$11.5B
Interventional
23.9%$5.2B
Life Sciences
23.7%$5.2B
AVTRAvantor, Inc.
FY 2025
Proprietary Materials And Consumables
52.6%$3.4B
Third Party Materials And Consumables
47.4%$3.1B
BAXBaxter International Inc.
FY 2025
Medical Products And Therapies
48.8%$5.3B
Healthcare Systems and Technologies
28.3%$3.1B
Pharmaceuticals
22.9%$2.5B
TMOThermo Fisher Scientific Inc.
FY 2025
Consumables
41.9%$18.7B
Service
41.7%$18.6B
Instruments
16.4%$7.3B

STVN vs BDX vs AVTR vs BAX vs TMO — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLBDXLAGGINGBAX

Income & Cash Flow (Last 12 Months)

TMO leads this category, winning 5 of 6 comparable metrics.

TMO is the larger business by revenue, generating $45.2B annually — 38.2x STVN's $1.2B. TMO is the more profitable business, keeping 15.2% of every revenue dollar as net income compared to BAX's -9.7%. On growth, TMO holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSTVN logoSTVNStevanato Group S…BDX logoBDXBecton, Dickinson…AVTR logoAVTRAvantor, Inc.BAX logoBAXBaxter Internatio…TMO logoTMOThermo Fisher Sci…
RevenueTrailing 12 months$1.2B$21.4B$6.6B$11.3B$45.2B
EBITDAEarnings before interest/tax$283M$4.2B$137M$671M$10.5B
Net IncomeAfter-tax profit$139M$1.1B-$551M-$1.1B$6.9B
Free Cash FlowCash after capex$16M$3.1B$439M$501M$6.7B
Gross MarginGross profit ÷ Revenue+29.0%+46.5%+32.1%+30.1%+39.4%
Operating MarginEBIT ÷ Revenue+16.5%+10.6%-4.3%-2.7%+17.8%
Net MarginNet income ÷ Revenue+11.8%+5.3%-8.4%-9.7%+15.2%
FCF MarginFCF ÷ Revenue+1.4%+14.7%+6.7%+4.4%+14.9%
Rev. Growth (YoY)Latest quarter vs prior year+3.8%-10.6%0.0%+2.9%+6.2%
EPS Growth (YoY)Latest quarter vs prior year-5.6%-2.0%-32.6%-112.0%+11.3%
TMO leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

AVTR leads this category, winning 3 of 7 comparable metrics.

At 26.3x trailing earnings, BDX trades at a 16% valuation discount to STVN's 31.3x P/E. Adjusting for growth (PEG ratio), BDX offers better value at 1.59x vs TMO's 12.67x — a lower PEG means you pay less per unit of expected earnings growth.

MetricSTVN logoSTVNStevanato Group S…BDX logoBDXBecton, Dickinson…AVTR logoAVTRAvantor, Inc.BAX logoBAXBaxter Internatio…TMO logoTMOThermo Fisher Sci…
Market CapShares × price$4.9B$55.5B$5.7B$9.0B$176.4B
Enterprise ValueMkt cap + debt − cash$5.3B$73.9B$9.3B$17.1B$207.4B
Trailing P/EPrice ÷ TTM EPS31.31x26.29x-10.65x-10.01x26.75x
Forward P/EPrice ÷ next-FY EPS est.29.32x12.27x10.57x9.17x19.11x
PEG RatioP/E ÷ EPS growth rate2.64x1.59x12.67x
EV / EBITDAEnterprise value multiple16.89x14.65x56.43x25.37x19.04x
Price / SalesMarket cap ÷ Revenue3.68x2.54x0.87x0.80x3.96x
Price / BookPrice ÷ Book value/share2.82x1.73x1.01x1.47x3.34x
Price / FCFMarket cap ÷ FCF195.36x20.80x11.46x27.99x28.02x
AVTR leads this category, winning 3 of 7 comparable metrics.

Profitability & Efficiency

STVN leads this category, winning 6 of 9 comparable metrics.

TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-16 for BAX. STVN carries lower financial leverage with a 0.32x debt-to-equity ratio, signaling a more conservative balance sheet compared to BAX's 1.64x. On the Piotroski fundamental quality scale (0–9), BDX scores 7/9 vs BAX's 5/9, reflecting strong financial health.

MetricSTVN logoSTVNStevanato Group S…BDX logoBDXBecton, Dickinson…AVTR logoAVTRAvantor, Inc.BAX logoBAXBaxter Internatio…TMO logoTMOThermo Fisher Sci…
ROE (TTM)Return on equity+9.7%+4.5%-9.6%-16.5%+13.2%
ROA (TTM)Return on assets+5.8%+2.1%-4.6%-5.4%+6.4%
ROICReturn on invested capital+7.7%+4.3%-2.0%-1.4%+7.5%
ROCEReturn on capital employed+9.5%+5.4%-2.4%-1.7%+9.1%
Piotroski ScoreFundamental quality 0–957556
Debt / EquityFinancial leverage0.32x0.76x0.71x1.64x0.76x
Net DebtTotal debt minus cash$340M$18.3B$3.6B$8.0B$31.0B
Cash & Equiv.Liquid assets$131M$851M$365M$2.0B$9.9B
Total DebtShort + long-term debt$471M$19.2B$3.9B$10.0B$40.9B
Interest CoverageEBIT ÷ Interest expense20.54x4.09x-1.55x-0.83x5.89x
STVN leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

BDX leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in BDX five years ago would be worth $11,693 today (with dividends reinvested), compared to $2,566 for BAX. Over the past 12 months, BDX leads with a +51.8% total return vs BAX's -41.8%. The 3-year compound annual growth rate (CAGR) favors BDX at 1.6% vs AVTR's -25.5% — a key indicator of consistent wealth creation.

MetricSTVN logoSTVNStevanato Group S…BDX logoBDXBecton, Dickinson…AVTR logoAVTRAvantor, Inc.BAX logoBAXBaxter Internatio…TMO logoTMOThermo Fisher Sci…
YTD ReturnYear-to-date-12.4%+0.7%-27.5%-10.2%-19.8%
1-Year ReturnPast 12 months-17.0%+51.8%-30.4%-41.8%+16.8%
3-Year ReturnCumulative with dividends-35.9%+5.0%-58.6%-56.3%-11.7%
5-Year ReturnCumulative with dividends-7.2%+16.9%-73.4%-74.3%+2.8%
10-Year ReturnCumulative with dividends-7.2%+80.2%-42.7%-42.4%+229.1%
CAGR (3Y)Annualised 3-year return-13.8%+1.6%-25.5%-24.1%-4.0%
BDX leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

BDX leads this category, winning 2 of 2 comparable metrics.

BDX is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than AVTR's 1.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BDX currently trades 74.6% from its 52-week high vs AVTR's 52.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSTVN logoSTVNStevanato Group S…BDX logoBDXBecton, Dickinson…AVTR logoAVTRAvantor, Inc.BAX logoBAXBaxter Internatio…TMO logoTMOThermo Fisher Sci…
Beta (5Y)Sensitivity to S&P 5001.45x0.66x1.54x1.37x1.10x
52-Week HighHighest price in past year$28.00$205.52$15.93$32.68$643.99
52-Week LowLowest price in past year$12.89$100.31$7.26$15.73$385.46
% of 52W HighCurrent price vs 52-week peak+64.4%+74.6%+52.2%+53.6%+73.7%
RSI (14)Momentum oscillator 0–10082.132.258.144.043.1
Avg Volume (50D)Average daily shares traded583K2.5M8.9M8.7M1.9M
BDX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — BAX and TMO each lead in 1 of 2 comparable metrics.

Analyst consensus: STVN as "Buy", BDX as "Buy", AVTR as "Hold", BAX as "Hold", TMO as "Buy". Consensus price targets imply 38.0% upside for TMO (target: $655) vs 12.8% for BDX (target: $173). For income investors, BAX offers the higher dividend yield at 3.87% vs STVN's 0.34%.

MetricSTVN logoSTVNStevanato Group S…BDX logoBDXBecton, Dickinson…AVTR logoAVTRAvantor, Inc.BAX logoBAXBaxter Internatio…TMO logoTMOThermo Fisher Sci…
Analyst RatingConsensus buy/hold/sellBuyBuyHoldHoldBuy
Price TargetConsensus 12-month target$24.50$172.85$9.50$19.75$654.67
# AnalystsCovering analysts833263642
Dividend YieldAnnual dividend ÷ price+0.3%+2.7%+3.9%+0.4%
Dividend StreakConsecutive years of raises01008
Dividend / ShareAnnual DPS$0.05$4.17$0.68$1.69
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.8%+1.4%0.0%+1.7%
Evenly matched — BAX and TMO each lead in 1 of 2 comparable metrics.
Key Takeaway

BDX leads in 2 of 6 categories (Total Returns, Risk & Volatility). TMO leads in 1 (Income & Cash Flow). 1 tied.

Best OverallBecton, Dickinson and Compa… (BDX)Leads 2 of 6 categories
Loading custom metrics...

STVN vs BDX vs AVTR vs BAX vs TMO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is STVN or BDX or AVTR or BAX or TMO a better buy right now?

For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.

2% revenue growth year-over-year, versus -3. 4% for Avantor, Inc. (AVTR). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (12. 3x forward), making it the more compelling value choice. Analysts rate Stevanato Group S. p. A. (STVN) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — STVN or BDX or AVTR or BAX or TMO?

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 26.

3x versus Stevanato Group S. p. A. at 31. 3x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 74x versus Thermo Fisher Scientific Inc. 's 9. 05x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — STVN or BDX or AVTR or BAX or TMO?

Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +16.

9%, compared to -74. 3% for Baxter International Inc. (BAX). Over 10 years, the gap is even starker: TMO returned +229. 1% versus AVTR's -42. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — STVN or BDX or AVTR or BAX or TMO?

By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.

66β versus Avantor, Inc. 's 1. 54β — meaning AVTR is approximately 135% more volatile than BDX relative to the S&P 500. On balance sheet safety, Stevanato Group S. p. A. (STVN) carries a lower debt/equity ratio of 32% versus 164% for Baxter International Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — STVN or BDX or AVTR or BAX or TMO?

By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.

2% versus -3. 4% for Avantor, Inc. (AVTR). On earnings-per-share growth, the picture is similar: Stevanato Group S. p. A. grew EPS 14. 0% year-over-year, compared to -175. 0% for Avantor, Inc.. Over a 3-year CAGR, STVN leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — STVN or BDX or AVTR or BAX or TMO?

Thermo Fisher Scientific Inc.

(TMO) is the more profitable company, earning 15. 1% net margin versus -8. 5% for Baxter International Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus -3. 8% for AVTR. At the gross margin level — before operating expenses — BDX leads at 45. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is STVN or BDX or AVTR or BAX or TMO more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 74x versus Thermo Fisher Scientific Inc. 's 9. 05x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Baxter International Inc. (BAX) trades at 9. 2x forward P/E versus 29. 3x for Stevanato Group S. p. A. — 20. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 0% to $654. 67.

08

Which pays a better dividend — STVN or BDX or AVTR or BAX or TMO?

In this comparison, BAX (3.

9% yield), BDX (2. 7% yield), TMO (0. 4% yield), STVN (0. 3% yield) pay a dividend. AVTR does not pay a meaningful dividend and should not be held primarily for income.

09

Is STVN or BDX or AVTR or BAX or TMO better for a retirement portfolio?

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 7% yield). Avantor, Inc. (AVTR) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BDX: +80. 2%, AVTR: -42. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between STVN and BDX and AVTR and BAX and TMO?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: STVN is a small-cap quality compounder stock; BDX is a mid-cap quality compounder stock; AVTR is a small-cap quality compounder stock; BAX is a small-cap income-oriented stock; TMO is a mid-cap quality compounder stock. BDX, BAX pay a dividend while STVN, AVTR, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

STVN

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

BDX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 1.0%
Run This Screen
Stocks Like

AVTR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 19%
Run This Screen
Stocks Like

BAX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 18%
  • Dividend Yield > 1.5%
Run This Screen
Stocks Like

TMO

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 9%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform STVN and BDX and AVTR and BAX and TMO on the metrics below

Revenue Growth>
%
(STVN: 3.8% · BDX: -10.6%)
Net Margin>
%
(STVN: 11.8% · BDX: 5.3%)
P/E Ratio<
x
(STVN: 31.3x · BDX: 26.3x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.